bortezomib + rituximab

DRUG2 trials

Sponsors

Jonsson Comprehensive Cancer Center, Millennium Pharmaceuticals, Inc.

Conditions

LymphomaNon-Hodgkin's Lymphoma

Phase 2

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

CompletedNCT00093769

Jonsson Comprehensive Cancer CenterLymphoma

Start: 2004-08-31Updated: 2012-10-04

Phase 3

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

CompletedNCT00312845

Millennium Pharmaceuticals, Inc.Non-Hodgkin's Lymphoma

Start: 2006-03-31End: 2010-07-31Updated: 2012-06-25

Related Papers

Evaluation of Lenalidomide & Rituximab in Indolent Lymphoma

Oncology Times2019-05-13

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.

2012-10-2217 citations

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

2011-07-0171 citations